Tc Biopharm Holdings Stock Probability of Future Stock Price Finishing Under 3.65
TCBP Stock | USD 0.60 0.04 6.25% |
TCBP |
TC BioPharm Target Price Odds to finish below 3.65
The tendency of TCBP Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to stay under $ 3.65 after 90 days |
0.60 | 90 days | 3.65 | about 46.05 |
Based on a normal probability distribution, the odds of TC BioPharm to stay under $ 3.65 after 90 days from now is about 46.05 (This TC BioPharm Holdings probability density function shows the probability of TCBP Stock to fall within a particular range of prices over 90 days) . Probability of TC BioPharm Holdings price to stay between its current price of $ 0.60 and $ 3.65 at the end of the 90-day period is about 37.05 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.14 . This usually implies TC BioPharm Holdings market returns are sensible to returns on the market. As the market goes up or down, TC BioPharm is expected to follow. Additionally TC BioPharm Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. TC BioPharm Price Density |
Price |
Predictive Modules for TC BioPharm
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as TC BioPharm Holdings. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.TC BioPharm Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. TC BioPharm is not an exception. The market had few large corrections towards the TC BioPharm's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold TC BioPharm Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of TC BioPharm within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.83 | |
β | Beta against Dow Jones | 1.14 | |
σ | Overall volatility | 2.46 | |
Ir | Information ratio | -0.14 |
TC BioPharm Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of TC BioPharm for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for TC BioPharm Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.TC BioPharm Holdings generated a negative expected return over the last 90 days | |
TC BioPharm Holdings has high historical volatility and very poor performance | |
TC BioPharm Holdings has some characteristics of a very speculative penny stock | |
TC BioPharm Holdings has a very high chance of going through financial distress in the upcoming years | |
TC BioPharm Holdings currently holds 1.8 M in liabilities. TC BioPharm Holdings has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
TC BioPharm Holdings currently holds about 1.57 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
TC BioPharm Holdings has a very weak financial position based on the latest SEC disclosures | |
Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in TC BioPharm PLC |
TC BioPharm Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of TCBP Stock often depends not only on the future outlook of the current and potential TC BioPharm's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. TC BioPharm's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 30.9 K | |
Cash And Short Term Investments | 2.5 M | |
Shares Float | 98.4 M |
TC BioPharm Technical Analysis
TC BioPharm's future price can be derived by breaking down and analyzing its technical indicators over time. TCBP Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of TC BioPharm Holdings. In general, you should focus on analyzing TCBP Stock price patterns and their correlations with different microeconomic environments and drivers.
TC BioPharm Predictive Forecast Models
TC BioPharm's time-series forecasting models is one of many TC BioPharm's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary TC BioPharm's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about TC BioPharm Holdings
Checking the ongoing alerts about TC BioPharm for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for TC BioPharm Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
TC BioPharm Holdings generated a negative expected return over the last 90 days | |
TC BioPharm Holdings has high historical volatility and very poor performance | |
TC BioPharm Holdings has some characteristics of a very speculative penny stock | |
TC BioPharm Holdings has a very high chance of going through financial distress in the upcoming years | |
TC BioPharm Holdings currently holds 1.8 M in liabilities. TC BioPharm Holdings has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
TC BioPharm Holdings currently holds about 1.57 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
TC BioPharm Holdings has a very weak financial position based on the latest SEC disclosures | |
Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in TC BioPharm PLC |
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.